Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy for Head and Neck Squamous Cell Carcinoma

  • Oral Neoplasia (F Alawi and A Le, Section Editors)
  • Published:
Current Oral Health Reports Aims and scope Submit manuscript

Abstract

Head and neck squamous cell carcinoma has been found to be an immunosuppressive malignancy, with many defects in the host immune system contributing to the progression of disease. A greater understanding of these defects has lead to the identification and investigation of new therapeutic strategies, targeting immune system dysfunction in an effort to improve the outcomes of this disease. This article provides a brief review of the knowledge regarding the immune defects present in head and neck cancer, as well as a review of the current therapeutic strategies being investigated for use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:3755.

    Article  CAS  PubMed  Google Scholar 

  2. Hoffmann TK, Dworacki G, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8:2553–62.

    PubMed  Google Scholar 

  3. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999;5:1369.

    CAS  PubMed  Google Scholar 

  4. Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:28. This article provides an excellent review of immunology related to carcinoma. It provides excellent background information of immunology in general, and provides a nice review of the state of the field currently.

    Article  Google Scholar 

  5. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4 + CD25+ regulatory t cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92:913–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4 + CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppresion in the tumor microenvironment. Clin Cancer Res. 2007;13:4345–54.

    Article  CAS  PubMed  Google Scholar 

  7. Ferris R, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12:3890–5.

    Article  CAS  PubMed  Google Scholar 

  8. Whiteside TL. Immune cells in the tumor microenvironment: mechanisms responsible for functional and signaling defects. Adv Exp Med Biol. 1998;451:161–71.

    Google Scholar 

  9. Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW, Chatterjee SK. Inhibition of NK cell activity through TGF-beta1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol. 2005;175:5541–50.

    Article  CAS  PubMed  Google Scholar 

  10. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755–66.

    CAS  PubMed  Google Scholar 

  11. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014;2:14.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 2013;49:1089–96.

    Article  PubMed  Google Scholar 

  14. Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl. 1993;17F:188–91.

    Article  CAS  PubMed  Google Scholar 

  15. Eisma RJ, Spiro JD, Kreutzer DL. Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope. 1999;109:687–93.

    Article  CAS  PubMed  Google Scholar 

  16. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824–32.

    Article  Google Scholar 

  17. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19:1858–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28:4390–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bauman JE, Ferris RL. Integrating novel therapeutic monoclonal antibodies in the management of head and neck cancer. Cancer. 2014;120:624–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without Gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013;31:1405–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al. Cisplatin and radiotherapy with or without Erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013;31:1415–21.

    Article  CAS  PubMed  Google Scholar 

  22. Giralt J, Trigo J, Nuyts S, Ozsahin M, Skiadowski K, Hatoum G, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16:221–32.

    Article  CAS  PubMed  Google Scholar 

  23. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.

    Article  CAS  PubMed  Google Scholar 

  24. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer. 2008;112:2710–9.

    Article  CAS  PubMed  Google Scholar 

  25. Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, Erfan J, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011;22:1078–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Licitra L, Storkel S, Kerr KM, Cutsem EV, Pirker R, Hirsch FR, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013;49:1161–8.

    Article  CAS  PubMed  Google Scholar 

  27. Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. Cancer Biol Ther. 2010;10:673–81.

    Article  CAS  PubMed  Google Scholar 

  28. Reddy BK, Lokesh V, Vidyasagar MS, Shenoy K, Babu KG, Shenoy A, et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol. 2014;50:498–505.

    Article  CAS  PubMed  Google Scholar 

  29. Swanson MS, Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data. Oral Oncol. 2015;51:12–5.

    Article  CAS  PubMed  Google Scholar 

  30. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.

    Article  CAS  PubMed  Google Scholar 

  32. Jie H, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, et al. CTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75:2200–10.

    Article  CAS  PubMed  Google Scholar 

  33. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

    Article  CAS  PubMed  Google Scholar 

  34. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.

    Article  CAS  PubMed  Google Scholar 

  35. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47:1148–53.

    Article  CAS  PubMed  Google Scholar 

  36. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501–5.

    CAS  PubMed  Google Scholar 

  37. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Seiwert TY. A phase IB study of MK-3475 in patients with human papillomavirus (HPV)- associated and non-HPV associated head and neck (h/n) cancer. 2014 ASCO Annu Meet. 32 2014.

  39. Starr P. Encouraging results for pembrolizumab in head and neck cancer. Am Health Drug Benefits. 2015;8:16. This study has not yet published its final results, but results are encouraging showing improvement over Cetuximab for treatment of HNSCC. These results if they show improvement over Cetuximab, would provide evidence of another immunologic target for squamous cell carcinoma.

    PubMed  PubMed Central  Google Scholar 

  40. Seiwert TY, Burtness B, Weiss M, Eder JP, Yearley J, Murphy E, Nebozhyn M, McClanahan T, Ayers M, Lunceford J, Mehra R, Heath K, Cheng J, Chow L. Inflamed-phenotype gene expression signatures, and in particular a gamma-interferon signature, predicted benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. ASPO. 2015.

  41. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, Vasselli J, Ibrahim RA, Lutzky J, Khleif S. Preliminary data from a multi-arm expansion study of medi4736, an anti-pd-l1 antibody. ASCO Annu Meet. 2014.

  42. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol. 1995;146:1029–39.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–64.

    Article  CAS  PubMed  Google Scholar 

  44. Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR, et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck. 2002;24:1004–11.

    Article  PubMed  Google Scholar 

  45. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096–103.

    Article  CAS  PubMed  Google Scholar 

  46. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther. 2007;7:449–60.

    Article  CAS  PubMed  Google Scholar 

  47. Kyzas PA, Cunha IW, Ioannidis JPA. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11:1434–40.

    Article  CAS  PubMed  Google Scholar 

  48. Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29:1140–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008;26:1732–41.

    Article  CAS  PubMed  Google Scholar 

  50. Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, et al. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate stage and T4N0-1 head and neck cancers. Ann Oncol. 2011;22:2304–9.

    Article  CAS  PubMed  Google Scholar 

  51. Hainsworth JD, Spigel DR, Greco FA, Shipley DL, Peyton J, Mark R, et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J. 2011;17:267–72.

    Article  CAS  PubMed  Google Scholar 

  52. Yoo DS, Kirkpatrick JP, Craciunescu O, Broadwater G, Peterson BL, Carroll MD, et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res. 2012;18:1404–14.

    Article  CAS  PubMed  Google Scholar 

  53. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10:247–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Fury MG, Lee NY, Sherman E, Lisa D, Kelly K, Lipson B, et al. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer. 2012;118:5008–14.

    Article  CAS  PubMed  Google Scholar 

  55. Fury MG, Xiao H, Sherman EJ, Baxi S, Smith-Marrone S, Schupak K, Gewanter R, Gelblum D, Haque S, Schoder H, Shah JP, Katabi N, Kurtzman R, Lipson B, Cox L, Lee NY, Pfister DG. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck. 2015.

  56. Argiris A, Kotsaki AP, Hoang T, Worden FP, Savvides P, Gibson MK, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24:220–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Chung TK, Warram J, Day KE, Hartman Y, Rosenthal EL. Time-dependent pretreatment with bevacizumab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol Ther. 2015;16:790–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Yao M, Galanopoulous N, Lavertu P, Fu P, Gibson M, Argiris A, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced carcinoma of the head and neck. Head Neck. 2015;37:1665–71.

    Article  PubMed  Google Scholar 

  59. Swiecicki PL, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey T, Worden FP. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Investig New Drugs. 2015.

  60. Li Q, Prince ME, Moyer JS. Immunotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2015;51(4):299–304.

    Article  PubMed  Google Scholar 

  61. Jiang P, Zhang Y, Archibald SJ, Wang H. Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol. 2015;28:208–14.

    Article  CAS  PubMed  Google Scholar 

  62. Bloy N, Buque A, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. Trial watch: naked and vectored DNA-based anticancer vaccines. OncoImmunology. 2015;4:e1026531.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, et al. Therapeutic cancer vaccines. Adv Cancer Res. 2014;121:67–124.

    Article  CAS  PubMed  Google Scholar 

  64. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8:108–20.

    Article  CAS  PubMed  Google Scholar 

  65. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012;8:599–613.

    Article  Google Scholar 

  66. Schuler PJ, Harasymczuk M, Visus C, DeLeo A, Trivedi S, Lei Y, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014;20:2433–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Lu L, Tao H, Chang AE, Hu Y, Shu G, Chen Q, et al. Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. OncoImmunology. 2015;9:e990767.

    Article  Google Scholar 

  68. Siveen KS, Kuttan G. Role of macrophages in tumor progression. Immunol Lett. 2009;123:97–102.

    Article  CAS  PubMed  Google Scholar 

  69. Wang T, Niu G, Kottylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by stat-3 signaling in tumor cells. Nat Med. 2004;1:48–54.

    Article  Google Scholar 

  70. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting STAT3 signalling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;12:1314–21.

    Article  Google Scholar 

  71. Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, et al. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology. 2001;2:110–5.

    Article  Google Scholar 

  72. DeStefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer. 2002;95:90–7.

    Article  Google Scholar 

  73. Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, et al. Evidence for local and systemic activation of immune cells by peritumoral injectios of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993;53:5654–62.

    CAS  PubMed  Google Scholar 

  74. Wolf GT, Fee WE, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, et al. Novel neoadjuvant immunotherapt regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011;12:1666–74.

    Article  Google Scholar 

  75. Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, et al. Increased lymphocyte infiltration in patients with head and neck cancer treated with IRX-2 immunotherapy regimen. Cancer Immunol Immunother. 2012;6:771–82.

    Article  Google Scholar 

  76. Schilling B, Halstead ES, Schuler P, Harasymczuk M, Egan JE, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients. Cancer Immunol Immunother. 2012;9:1395–405.

    Article  Google Scholar 

  77. Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. PLoS One. 2013;2:e7234.

    Google Scholar 

  78. Richtsmeier WJ, Koch WM, McGuire WP, Poole ME, Chang EH. Phase I–II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg. 1990;116:1271–7.

    Article  CAS  PubMed  Google Scholar 

  79. Seixas-Silva JA, Richards T, Khuri FR, Wieand HS, Kim E, Murphy B, et al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long term follow-up. Arch Otolaryngol Head Neck Surg. 2005;131:304–7.

    Article  PubMed  Google Scholar 

  80. Urba SG, Forastiere AA, Wolf GT, Amrein PC. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous cell carcinoma. Cancer. 1993;71:2326–31.

    Article  CAS  PubMed  Google Scholar 

  81. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234–41.

    Article  CAS  PubMed  Google Scholar 

  82. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85:293–5.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. OncoImmunology. 2015;4:e1046028.

    Article  PubMed  Google Scholar 

  85. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–65.

    Article  PubMed  Google Scholar 

  86. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342.

    CAS  PubMed  Google Scholar 

  87. Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy. Nat Rev Clin Oncol. 2014;11:413–31.

    Article  CAS  PubMed  Google Scholar 

  88. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008;20:504–11.

    Article  CAS  PubMed  Google Scholar 

  89. Kaneno R, Shurin GV, Tourkova IL, Shurin MR. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med. 2009;10:58.

    Article  Google Scholar 

  90. Kaneno R, Shurin GV, Kaneno FM, Naiditch H, Luo J, Shurin MR. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol. 2011;34:97–106.

    Article  CAS  Google Scholar 

  91. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–8.

    Article  CAS  PubMed  Google Scholar 

  92. Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res. 2012;32:5363–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive - SPC 5312, Ann Arbor, MI, 48109, USA

    Rebecca C. Hoesli & Jeffrey S. Moyer

Authors
  1. Rebecca C. Hoesli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey S. Moyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey S. Moyer.

Ethics declarations

Conflict of Interest

Rebecca C. Hoesli and Jeffrey S. Moyer declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Oral Neoplasia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoesli, R.C., Moyer, J.S. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr Oral Health Rep 3, 74–81 (2016). https://doi.org/10.1007/s40496-016-0082-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40496-016-0082-2

Keywords

Search

Navigation